$144 Million

Atreca, Inc.

Initial Public Offering

Lead Left Bookrunner, June 2019

Atreca, Inc.
Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Atreca’s approach to drug development relies on the human immune system to direct it to